Optics

光学

• 批准号: 7611650
• 负责人: THOMAS Harrison FOSTER
• 金额: $ 19.41万
• 依托单位: ROSWELL PARK CANCER INSTITUTE CORP
• 依托单位国家: 美国
• 财政年份: 2008
• 资助国家: 美国
• 起止时间: 2008-12-01 至 2013-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7611650
• 关键词: Area; Cells; Clinic; Clinical; Clinical Trials; Deposition; Development; Device or Instrument Development; Dose; Elements; Engineering; Fiber; Fluorescence; Funding; Gene Expression; Image; Individual; Laboratories; Lasers; Lesion; Maintenance; Malignant Neoplasms; Methods; Microscopic; Modeling; Monitor; Normal tissue morphology; Optics; Patients; Perfusion; Pharmaceutical Preparations; Photobleaching; Photochemotherapy; Photosensitizing Agents; Physics; Reporting; Resolution; Role; Roswell Park Cancer Institute; Spectrum Analysis; System; Techniques; United States; design; dosimetry; fluorescence imaging; imaging modality; improved; in vivo; instrument; mathematical model; molecular imaging; optical imaging; pre-clinical; pre-clinical research; programs; response; therapy development; tomography; tumor

The purpose of this new, reorganized Core is to provide physics, optical imaging and spectroscopy, and mathematical modeling support for the PPG. In so doing, we anticipate that new methods and approaches will be developed in close connection to the specific aims of the 5 individual projects. Optics is of course a critical element of PDT, and optical dosimetry has been a theme of the Core from the beginning. The new scientific emphasis of the Core builds on the realization that there are significant opportunities to exploit advances in biomedical optics within the context of preclinical and clinical PDT. Because of its long tradition of bringing PDT from the laboratory to the clinic, Roswell Park Cancer Institute (RPCI) is perhaps uniquely situated in the United States to make breakthroughs in this area. Exciting opportunities exist on several levels. For example, the lesions treated by PDT are necessarily optically accessible, and this enables integration of optical spectroscopic monitoring with the delivery of PDT. The photosensitizers used in PDT fluoresce, and this renders them directly detectable via fluorescence imaging in cells and in vivo. Advances in molecular imaging strategies have made it possible to image therapy-induced gene expression, tumor and normal tissue vasculature, and host cell responses to treatment in vivo at subcellular resolution. Important advances in understanding the various factors that contribute to the microscopic deposition of photodynamic dose have led to the development of new and very powerful mathematical models of PDT dosimetry, which have the capability of informing and being informed by ongoing and planned clinical trials. An additional important role for the Core is to continue to provide outstanding technical support for the preclinical and clinical laser and fiber delivery systems that are integral to each of the projects. The specific aims of the Optical Spectroscopy, Molecular Imaging, and Dosimetry Modeling Core are: 1) To continue to provide technical and scientific support for the clinical instrument that integrates PDT delivery with fluorescence and reflectance spectroscopy; 2) To develop in vivo molecular imaging methods in close connection to all projects; 3) To utilize a new model of microscopic PDT dosimetry to inform the design and interpretation of clinical trials; and 4) To provide routine engineering and optics support for the clinical and preclinical research efforts of the PPG.

这个新的，重组的核心的目的是提供物理，光学成像和光谱， PPG的数学建模支持。在这样做时，我们预计，新的方法和途径， 将与5个项目的具体目标密切相关。光学当然是一个 光动力治疗的关键要素，光学剂量学从一开始就是核心的主题。新 对核心的科学强调是建立在这样一种认识的基础上的，即存在着重大的机会可以利用 在临床前和临床PDT背景下的生物医学光学进展。由于其悠久的传统 将PDT从实验室带到临床，罗斯韦尔公园癌症研究所（RPCI）可能是独一无二的 位于美国，在这一领域取得突破。几个方面存在令人兴奋的机会 程度.例如，通过PDT治疗的病变必须是光学可及的，并且这使得能够 光学光谱监测与PDT递送的整合。PDT中使用的光敏剂 荧光，这使得它们可以通过细胞和体内的荧光成像直接检测。进展 在分子成像策略中，已经使成像治疗诱导的基因表达、肿瘤和 正常组织脉管系统和亚细胞分辨率下的宿主细胞对体内治疗的反应。重要 在理解有助于光动力的微观沉积的各种因素方面的进展 剂量导致了新的和非常强大的PDT剂量学数学模型的发展， 有能力告知正在进行的和计划中的临床试验，并获得这些试验的信息。额外 核心的重要作用是继续为临床前和 临床激光和光纤传输系统是每个项目的组成部分。该委员会的具体目标 光谱学、分子成像和剂量学建模核心是：1）继续提供 为整合PDT输送与荧光的临床仪器提供技术和科学支持， 反射光谱; 2）开发与所有相关的体内分子成像方法 3）利用一种新的显微PDT剂量测定模型， 临床试验;以及4）为临床和临床前提供常规工程和光学支持 PPG的研究成果。